利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.01 秒)

    ANTI-INFLAMMATORY ANALGESIC ADHESIVE PATCH FOR EXTERNAL USE
    6.
    发明公开
    ANTI-INFLAMMATORY ANALGESIC ADHESIVE PATCH FOR EXTERNAL USE 有权
    ENTZÜNDUNGSHEMMENDESUND SCHMERZSTILLESES HEFTPFLASTER ZUR EXTERNEN ANWENDUNG

    公开(公告)号：EP2524692A1

    公开(公告)日：2012-11-21

    申请号：EP11731785.9

    申请日：2011-01-05

    申请人： Teikoku Seiyaku Co., Ltd. ,  Ibsa Institut Biochimique S.A.

    发明人： SHIBATA, Taiki ,  MABUCHI, Yuichiro ,  HATTORI, Kenichi ,  KAMAKURA, Takashi

    IPC分类号： A61K31/40 ,  A61K9/70 ,  A61K47/10 ,  A61K47/20 ,  A61K47/22 ,  A61K47/32

    CPC分类号： A61K31/40 ,  A61K9/7053 ,  A61K9/7076 ,  A61K31/196 ,  Y10T156/10 ,  A61K2300/00

    摘要： An external patch containing diclofenac hydroxyethylpyrrolidine prepared by laminating an adhesive layer on a backing, wherein said adhesive layer is characterized by comprising 5-50% by weight of styrene·isoprene·styrene block copolymer, 20-50% by weight of a tackifier resin, 5-70% by weight of a softening agent, and 0.5-20% by weight of one or more solubilizers selected from N-methyl-2-pyrrolidone, propylene glycol and dimethyl sulfoxide as essential ingredients, and 0.5-20% by weight of diclofenac hydroxyethylpyrrolidine as an active ingredient. The patch has excellent transdermal absorption, less skin-irritation and excellent stability of the drug.

    摘要翻译： 通过将粘合剂层层压在背衬上制备的含有双氯芬酸羟乙基吡咯烷的外部贴片，其中所述粘合剂层的特征在于包含5-50重量％的苯乙烯·异戊二烯·苯乙烯嵌段共聚物，20-50重量％的增粘树脂， 5-70重量％的软化剂和0.5-20重量％的一种或多种选自N-甲基-2-吡咯烷酮，丙二醇和二甲基亚砜作为必需成分的增溶剂，和0.5-20重量％ 双氯芬酸羟乙基吡咯烷作为活性成分。 该贴剂具有优异的透皮吸收，较少的皮肤刺激和优异的药物稳定性。

    FSH AND LH SEPARATION AND PURIFICATION PROCESS
    8.
    发明公开
    FSH AND LH SEPARATION AND PURIFICATION PROCESS 失效
    FSH和LH的分离和纯化过程

    公开(公告)号：EP0882064A1

    公开(公告)日：1998-12-09

    申请号：EP97950077.0

    申请日：1997-11-03

    申请人： IBSA - INSTITUT BIOCHIMIQUE S.A.

    发明人： LUALDI, Paolo ,  DONATI, Elisabetta ,  RAPAPORT, Irina

    IPC分类号： C07K14

    CPC分类号： C07K14/59

    摘要： A new process, particularly simple and economical, for FSH and LH separation and purification starting from crude HMG preferably urinary, comprising the following steps: optional exhaustion of crude HMG viral charge in aqueous EtOH; ion-exchange chromatography on weakly basic anionic resins of DEAE type; affinity chromatography on resin having an antraquinone derivative as a ligand; optional ion-exchange chromatography on strongly basic anionic resins. Hormones obtained thereby, in particularly pure form and having high specific activity, may subsequently undergo a depyrogenation step.